Billionaires John Paulson and D.E. Shaw Like This Stock

PAULSON & COAccording to 13F filings for the second quarter, D.E. Shaw increased its position in Mylan Inc (NASDAQ:MYL) by 19% between the beginning of April and the end of June to 16.9 million shares. Mylan, which develops and manufactures both generic and branded pharmaceutical products and ingredients, is also a favorite of billionaire John Paulson’s Paulson & Co. Paulson left its position in the company unchanged during the second quarter at 24.5 million shares. Paulson and D.E. Shaw have often increased and decreased their stakes in Mylan over the past several quarters, but at the end of June it was the fifth largest position in Paulson’s portfolio according to the fund’s 13F (see more stock picks from John Paulson and D.E. Shaw). So far this year Mylan is up 7%, underperforming the NASDAQ index, but it has risen an impressive 11% since the end of June.

The most common investment thesis behind Mylan is that as an increasing number of drugs go off-patent in the coming years, Mylan will be able to develop and sell generic equivalents. The vast majority of Mylan’s revenue is generated by generic drugs, though higher sales of its branded auto-injector for treating allergic reactions caused high growth in the branded segment. Overall, revenues increased 7% in the second quarter compared to the same period a year ago; earnings slightly decreased, but thanks to a fall in share count earnings per share were essentially unchanged. In the first half of 2012, Mylan saw a 7% increase in earnings, as revenue grew 9%, as well as the fall in share count. This drove its earnings per share up to 62 cents, compared to 56 cents in the first half of 2011.

Mylan’s second quarter report beat the Street’s earnings expectations, something the company had done in the previous three quarters as well. The beats have been narrow, but should give investors more confidence in the company’s ability to meet sell-side targets in the future. At the moment, analyst consensus is for earnings per share of $2.74 for 2013 and, with half the year in the books, $2.51 for 2012; this implies a 9% EPS growth rate next year, about in line with what it has done so far this year. The trend in patent expiration gives the company avenues to future growth, and Mylan has recently announced a partnership with Pfizer Inc (NYSE:PFE) to produce generic drugs for the Japanese market. The sell-side’s expectations imply a forward P/E of 9, which seems cheap, and going out further the five-year PEG ratio is 0.9.

The two closest peers for Mylan are Teva Pharmaceutical Industries Ltd (NYSE:TEVA) and Watson Pharmaceuticals Inc (NYSE:WPI). Both companies, similarly to Mylan, produce both generic and branded drugs. Teva is a monster value stock on a quantitative basis: it trades at 11 times trailing earnings, 7 times forward earnings estimates, and is coming off a 50% bump in earnings compared to the same period in the previous year. At a $35 billion market capitalization, it is also over three times Mylan’s size. Over the longer term, however, the sell-side has its growth coming in just under the smaller company’s and its five-year PEG ratio is 1. We still think it might be better to take the value and a 2.1% dividend yield now rather than trust the Street. Watson has high growth targets, with its earnings per share expected to increase 40% in 2013 compared to 2012; the forward P/E is 10, but this is higher than either of its peers we’ve discussed and depends on what looks to be quite a bit of optimism. Considering future growth prospects all three of these companies seem like good investments in the trend of generic pharmaceuticals. Mylan is certainly a good pick if investors believe that D.E. Shaw ‘s and Paulson’s positions outweigh the narrowly better value in quantitative terms at Teva.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!